Journal
DIGESTIVE DISEASES
Volume 30, Issue -, Pages 107-111Publisher
KARGER
DOI: 10.1159/000342732
Keywords
Crohn's disease; Deep remission; Treatment strategy
Categories
Funding
- Abbott Laboratories
- ActoGeniX
- Albireo Pharma
- Amgen
- AstraZeneca
- Bayer AG
- Biogen Idec
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- Cellerix
- Centocor
- ChemoCentryx
- Cosmo Technologies
- Danone Research
- Elan Pharmaceuticals
- Genetech
- Giuliani SpA
- Given Imaging
- GlaxoSmithKline
- Hutchison MediPharma
- Merck Sharp and Dohme Corp.
- Takeda
- Neovacs
- Ocera Therapeutics Inc.
- Otsuka America Pharmaceutical
- Pfizer
- Shire Pharmaceuticals
- Prometheus Laboratories
- Sanofi-Aventis
- Schering-Plough
- Synta Pharmaceuticals Corp.
- Teva
- Therakos
- Tillotts Pharma
- UCB Pharma
- Wyeth
- ActoGeniX NV
- AGI Therapeutics Inc.
- Alba Therapeutics Corp.
- Albireo
- Alfa Wasserman
- AM-Pharma BV
- Anaphore
- Astellas Pharma
- Athersys Inc.
- Atlantic Healthcare Ltd.
- Aptalis
- BioBalance Corporation
- Boehringer-Ingelheim Inc.
- Bristol Meyers Squibb
- Celegene
- Celek Pharmaceuticals
- Cellerix SL
- Cerimon Pharmaceuticals
- CoMentis
- Coronado Biosciences
- Cytokine Pharmasciences
- Eagle Pharmaceuticals
- Eisai Medical Research Inc.
- EnGene Inc.
- Eli Lilly
- Enteromedics
- Exagen Diagnostics Inc.
- Ferring Pharmaceuticals
- Flexion Therapeutics Inc.
- Funxional Therapeutics Ltd.
- Genzyme Corporation
- Roche
- Gilead Sciences
- Glaxo Smith Kline
- Human Genome Sciences
- Ironwood Pharmaceuticals
- Janssen
- KaloBios Pharmaceuticals Inc.
- Lexicon Pharmaceuticals
- Lycera Corporation
- Meda Pharmaceuticals
- Merck Research Laboratories
- MerckSerono
- Millennium Pharmaceuticals
- Nisshin Kyorin Pharmaceuticals Co. Ltd.
- Novo Nordisk A/S
- NPS Pharmaceuticals
- Optimer Pharmaceuticals
- Orexigen Therapeutics Inc.
- PDL Biopharma
- Procter and Gamble
- ProtAb Ltd.
- Purgenesis Technologies Inc.
- Receptos
- Relypsa Inc.
- Salient Pharmaceuticals
- Salix Pharmaceuticals Inc.
- Santarus
- Schering Plough Corp.
- Sigmoid Pharma Ltd.
- Sirtris Pharmaceuticals Inc. (a GSK company)
- S.L.A. Pharma (UK) Ltd.
- Targacept
- Teva Pharmaceuticals
- Tillotts Pharma AG
- TxCell SA
- Viamet Pharmaceuticals
- Vascular Biogenics Ltd. (VBL)
- Warner Chilcott UK Ltd.
- Genentech
- Novartis
- Procter and Gamble Pharmaceuticals
Ask authors/readers for more resources
Crohn's disease (CD) is a chronic inflammatory disorder characterized by periods of clinical remission alternating with periods of relapse defined by recurrent clinical symptoms. Persistent inflammation is believed to lead to progressive bowel damage over time, which manifests with the development of strictures, fistulae and abscesses. These disease complications frequently lead to a need for surgical resection, which in turn leads to disability. So CD can be characterized as a chronic, progressive, destructive and disabling disease. In rheumatoid arthritis, treatment paradigms have evolved beyond partial symptom control alone toward the induction and maintenance of sustained biological remission, also known as a 'treat to target' strategy, with the goal of improving long-term disease outcomes. In CD, there is currently no accepted, well-defined, comprehensive treatment goal that entails the treatment of both clinical symptoms and biologic inflammation. It is important that such a treatment concept begins to evolve for CD. A treatment strategy that delays or halts the progression of CD to increasing damage and disability is a priority. As a starting point, a working definition of sustained deep remission (that includes long-term biological remission and symptom control) with defined patient outcomes (including no disease progression) has been proposed. The concept of sustained deep remission represents a goal for CD management that may still evolve. It is not clear if the concept also applies to ulcerative colitis. Clinical trials are needed to evaluate whether treatment algorithms that tailor therapy to achieve deep remission in patients with CD can prevent disease progression and disability. Copyright (C) 2012 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available